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Background: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has stan-
dardized the reporting of thyroid cytology specimens. The objective of the current study was to 
evaluate the nationwide usage of TBSRTC and assess the malignancy rates in each category of 
TBSRTC in Korea. Methods: Questionnaire surveys were used for data collection on the fine nee-
dle aspiration (FNA) of thyroid nodules at 74 institutes in 2012. The incidences and follow-up ma-
lignancy rates of each category diagnosed from January to December, 2011, in each institute 
were also collected and analyzed. Results: Sixty out of 74 institutes answering the surveys re-
ported the results of thyroid FNA in accordance with TBSRTC. The average malignancy rates for 
resected cases in 15 institutes were as follows: nondiagnostic, 45.6%; benign, 16.5%; atypical of 
undetermined significance, 68.8%; suspicious for follicular neoplasm (SFN), 30.2%; suspicious 
for malignancy, 97.5%; malignancy, 99.7%. Conclusions: More than 80% of Korean institutes 
were using TBSRTC as of 2012. All malignancy rates other than the SFN and malignancy catego-
ries were higher than those reported by other countries. Therefore, the guidelines for treating pa-
tients with thyroid nodules in Korea should be revisited based on the malignancy rates reported 
in this study.
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The Bethesda System for Reporting Thyroid Cytopathology 
(TBSRTC) was developed to provide uniform terminology and 
diagnostic criteria for reporting thyroid fine needle aspiration 
(FNA) and to relate these cytologic diagnoses to clinical man-
agement.1 TBSRTC describes six categories for the diagnosis and 
reporting of thyroid FNAs, each with an assigned “risk of malig-
nancy” and associated recommendations for clinical management.1 
Since its implementation, many studies have demonstrated that 
TBSRTC has improved the quality of reporting by decreasing the 
number of ambiguous reports, increasing the positive predictive 
value of malignancy in thyroid glands that are operated, and 
decreasing the rates of surgery for benign thyroid nodules.2-5
TBSRTC terminology was incorporated into the 2009 guide-
lines of the Korean Thyroid Association (KTA) for management 
of patients with thyroid nodules and thyroid cancer.6 Several 
studies in Korea have demonstrated that TBSRTC well stratifies 
the malignancy risk by diagnostic categories and provides clinicians 
with useful information on the management of thyroid nodules.7-10 
However, a wide variation in the incidence and malignant risk 
of each diagnostic category (DC; from here on, we will use DC 
as the abbreviation of diagnostic category), especially of the 
atypia of undetermined significance/follicular lesion of undeter-
mined significance (AUS/FLUS) categories, has been reported.11,12 
Moreover, the malignant risk of the categories has been reported 
to be higher than the implied risk of malignancy in TBSRTC.7,9,13-15 
In the current study, we aimed to evaluate the extent of im-
plementation of TBSRTC for reporting thyroid FNAs and its 
impact on managing patients with thyroid nodules by assessing 
the incidence and malignancy rate in each category of TBSRTC 
in Korea.
MATERIALS AND METHODS
Design and data collection
A questionnaire designed by the Endocrine Pathology Study 
Group of the Korean Society of Pathologists to gather data con-
cerning the extent of implementation of TBSRTC and its impact 
on clinical practice was mailed to 211 pathology laboratories in 
the year 2012. Participants were asked questions related to the 
year of implementation of TBSRTC, number of thyroid aspiration 
cases in 2010 and 2011, usage of liquid-based cytology, types of 
liquid-based cytology used, and usage of core needle biopsy. 
Subsequently, a questionnaire was mailed to 41 institutions that 
had agreed to provide the statistics of thyroid FNA including the 
incidence, operation rate and malignancy rate of each diagnostic 
categories of TBSRTC. All the participants’ answers were collated. 
Among them, sixteen institutes reported the incidence of each 
category (unsatisfactory, benign, AUS, follicular neoplasm [FN], 
suspicious for malignancy [SM], and malignancy) in TBSRTC 
diagnosed from January to December, 2011. In total, 42,132 
cases were analyzed. Follow-up malignancy rates of each category 
in 15 institutes were also collected and analyzed. Malignancy rate of 
each category was estimated based on surgically resected specimens. 
This survey was approved by the Institutional Review Board of 
Seoul National University Bundang Hospital, waiving the require-
ment for informed consent (IRB No. B-1212/182-304).
Statistics
The statistical significance of the data was assessed using SPSS 
ver. 21.0 for Windows (IBM Corp., Armonk, NY, USA). The 
sensitivity, specificity, positive predictive value, and negative pre-
dictive value were calculated in two different settings considering 
thyroid FNA as a “screening test.” First, we calculated these pa-
rameters in malignant thyroid tumors. Surgical specimens which 
had been cytologically classified in the DC II of TBSRTC and 
diagnosed histologically as benign were considered to be true-
negative samples. Surgical specimens whose cytologic diagnoses 
were in the remaining diagnostic categories (DC V, DC VI) and 
histologically proved to be malignant neoplasms were considered 
to be true-positives. The false-positive category included cases 
that had been diagnosed as SM or malignant (DC V, DC VI), but 
later confirmed histologically as benign (normal, non-neoplastic 
benign lesion, or benign neoplasm). The false-negative cases 
included those diagnosed as benign on FNA but confirmed as 
malignant upon surgical excision. In addition, those parameters 
were calculated for thyroid neoplasms including benign (such as 
follicular adenoma) and malignant. For this calculation, follow-up 
surgical specimens diagnosed as non-neoplastic benign disease or 
normal, which were interpreted as the DC II of TBSRTC, were 
considered to be true-negative samples, and the remaining diag-
nostic categories (DC IV, DC V, and DC VI), which proved to be 
either benign or malignant neoplasms by histologic examination 
of the surgical specimens, were considered to be true-positive. 
The false-positive category included cases that were diagnosed 
as FN, SM, and malignant but later confirmed histologically as 
benign non-neoplastic or normal. The false-negative cases included 
those diagnosed as DC II on FNA but confirmed as a true neo-
plasm upon surgical excision. The DC I and DC III (AUS/FLUS) 
categories were excluded from the statistical analysis because 
these diagnoses usually led to a repeat FNA rather than to surgical 
excision; moreover, these cases could not be categorized as either 
positive or negative.
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RESULTS
General survey questions
Questionnaire surveys were sent out to 77 institutes of pa-
thology with controlled quality authorized by the Korean Cy-
topathology Conference. Three institutes were excluded because 
they were sending out their cytology specimens to consultants 
for the diagnosis, and answers from 74 institutes were included 
in the assessment. The survey results are summarized in Table 1. 
Among the 74 institutes, 60 used TBSRTC for their diagnostic 
categorization of thyroid FNA at the time of survey. The starting 
year of using this classification varied from 2008 to 2012. The 
usage increased particularly from 2010 to 2012, 3 to 5 years after 
the conference in Bethesda. In Korea, the corresponding guide-
lines of the KTA for management of patients with thyroid nodules 
and thyroid cancer were introduced in 2009, which might attri-
bute in the subsequent sharp rise in the usage of TBSRTC.6,16 
Forty-one out of the 74 institutes used conventional method for 
FNA, whereas 11 institutes used liquid-based method; the re-
maining 22 adopted both. Out of the 33 institutes using liquid-
based preparation, 10 had started doing so in 2010. Regarding 
the preparation method for liquid-based FNA, two representative 
commercial methods, Thin-prep and Sure-path, were predomi-
nant: almost every institute chose one or the other method. Core 
needle biopsy was being done in 21 institutes (27% of the 77). 
Among them, four institutes (5% of the 77) used both core needle 
biopsy and FNA as the primary investigation method of thyroid 
nodules. In thirty-eight institutes (51.4%), FNA was done by 
radiologists, followed by clinicians of internal medicine, surgeons, 
pathologists, and thyroid-specialized clinicians.
The survey indicated that the majority of the FNA specimens 
in Korea (60/74, 81%) were being diagnosed as per TBSRTC as 
of 2007. Moreover, the preparation method also shifted from 
conventional to liquid-based, the latter adopted in about 43% 
(33/77) including the institutes performing both. 
Incidence and malignancy rate of each DC of TBSRTC 
in Korea
Sixteen out of 74 institutes answering the survey reported the 
results of thyroid FNA by TBSRTC. The mean distribution of 
six categories from 42,132 cases of 16 institutes was as follows: 
11.1% nondiagnostic, 62.3% benign, 9.7% AUS, 0.9% FN, 
6.7% SM, and 9.1% malignancy (Table 2). The mean operation 
rates of each category were as follows: 7.5% nondiagnostic, 
2.4% benign, 20.2% AUS, 43.7% FN, 59.9% SM, and 69.2% 
malignancy (Table 3). 
The average of malignancy rates for resected cases of 15 insti-
tutes are shown in Table 4: nondiagnostic, 45.6%; benign, 16.5%; 
AUS, 68.7%; FN, 30.2%; SM, 97.5%; and malignancy, 99.7%. 
Relatively high malignancy rates were noted in nondiagnostic and 
benign categories, which might have resulted from false-negative 
results of clinically suspicious nodules. Overall, the false-positive 
rate of the SM and malignancy category combined was 1.23%.
Follow-up histologic diagnosis of each categories 
of TBSRTC
The final histological diagnoses upon resection are listed in 
Table 5. Each DC is sub-classified according to the recommen-
dation of TBSRTC and follow-up histologic diagnoses are sum-
marized by the sub-classification of each DC. 
Of 4,599 cases, 247 were operated in the non-DC (DC I) and 
Table 1. Summary of the survey
No. of institutions (%)
No. of institutions using TBSRTC 60/74 (81)
The starting year using TBSRTC 60
   2008 1
   2009 5
   2010 17
   2011 20
   2012 17
Methods of fine needle aspiration 74
   Conventional 41
   Liquid base 11
   Both 22
The starting year using liquid based cytology 33
   2000 1
   2002 1
   2006 1
   2007 2
   2008 5
   2009 5
   2010 10
   2011 3
   2012 3
   Others 2
Types of liquid based cytology 33
   Thin-prep 16
   Sure-path 16
   Others 1
Main department performing FNA on patients 74
   Radiology 38 (51.4)
   Pathology 2 (2.7)
   Internal medicine 21 (28.4)
   Surgery 12 (16.2)
   Thyroid clinician 1 (1.4)
TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; 
FNA, fine needle aspiration.
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128 cases (51.8%) were revealed as malignant nodules. The 
malignant cases mainly consisted of papillary thyroid carcinoma 
(121 cases), followed by five cases of follicular carcinoma, one case 
of poorly differentiated carcinoma, and one case of lymphoma. The 
benign category (DC II) had 422 cases of follow-up operation out of 
21,399 cases. Among them, 320 (75.8%) were revealed as benign 
nodules and 102 cases (24.2%) were malignant: 89 papillary thyroid 
carcinomas, 12 follicular carcinomas, and one medullary carcinoma. 
Out of the 3,708 AUS-categorized cases, 722 had follow-up surgical 
resection (Table 3). The 514 cases (71.2%) with malignant histo-
logic diagnoses consisted of 471 cases of papillary carcinoma, 25 
cases of follicular carcinoma, 13 of medullary carcinoma, four of 
Hurthle cell carcinoma, and one of poorly differentiated carcinoma. 
The remaining 208 (28.8%) cases were proved to be benign lesions. 
In DC VI (FN), 121 out of 283 cases had surgical resection. Forty-
six cases out of 121 cases (38%) were malignant: 23 cases of follicular 
carcinoma, 20 of papillary carcinoma, and three of Hurthle cell 
carcinoma. The remaining cases (75 cases, 61.9%) that were 
proved to be benign included 36 follicular adenomas, 19 nodular 
hyperplasia, 16 Hurthle cell adenomas, and four lymphocytic 
thyroiditis (Table 5). A total of 1,133 cases of DC V were histo-
logically confirmed as benign nodules in 32 cases (2.8 %) and ma-
lignancy in 1,101 cases (97.2%): 1,094 cases of papillary carcinoma 
and seven cases of medullary carcinoma (Table 5). Lastly, DC VI 
(malignancy) had 2,439 resected cases out of 3,343 FNAs. 
Overall, the final histologic diagnoses were well correlated with 
preoperative FNA diagnoses. Out of 2,439 cases, 2,419 (99.6%) 
with a preoperative diagnosis of papillary carcinoma on FNA 
sub-classification were proved to be papillary carcinoma upon 
resection. Only 20 out of 2,439 resected cases were non-papillary 
thyroid carcinoma lesions including one follicular carcinoma, three 
medullary carcinomas, two poorly differentiated carcinomas, one 
undifferentiated carcinoma, one metastatic carcinoma, and 12 
various benign lesions (Table 5). 
Diagnostic values for TBSRTC in Korea
Through the data obtained by the survey summarized above, 
sensitivity, specificity, positive predictive value, and negative 
predictive value were analyzed in two ways. First, we included only 
those in the benign category (DC II) as negative and malignant 
Table 2. The distribution of each diagnostic category of TBSRTC from 16 institutions
Diagnostic category
Total 
Range 
(%)
Mean ± SD 
(%)1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
UNS/ND 1,040 
(14.7)
386 
(21.2)
865 
(16.6)
199 
(10.7)
513 
(11.7)
185 
(10.0)
285 
(7.5)
64 
(8.0)
315 
(17.2)
400 
(13.1)
154 
(6.8)
208 
(10.4)
522 
(16.9)
39 
(6.4)
7 
(0.9)
97 
(5.8)
5,279 
(12.5)
0.9–21.2 11.1 ± 5.3
Benign 3,397 
(47.9)
1,045 
(57.4)
2,791 
(53.5)
978 
(52.5)
2,825 
(64.6)
1,099 
(59.7)
2,611 
(68.5)
409 
(50.9)
1,087 
(56.3)
2,218 
(72.7)
1,904 
(83.9)
1,512 
(75.2)
1,290 
(41.7)
441 
(72.4)
615 
(78.2)
1,014 
(60.8)
25,236 
(59.9)
41.7–83.9 62.3 ± 12.0
AUS 893 
(12.9)
190 
(10.4)
360 
(6.9)
369 
(19.8)
275 
(6.3)
159 
(8.6)
367 
(9.6)
117 
(14.6)
188 
(10.3)
248 
(8.1)
87 
(3.8)
81 
(4.0)
551 
(17.8)
55 
(9.0)
43 
(5.5)
117 
(7.0)
4,100 
(9.7)
3.8–19.8 9.7 ± 4.6
FN/SFN 55 
(0.7)
5 
(0.3)
38 
(0.7)
28 
(1.5)
93 
(2.1)
8 
(0.4)
14 
 (0.4)
5 
(0.6)
55 
(3.0)
11 
(0.4)
0 
(0)
4 
(0.2)
49 
(1.6)
1 
(0.2)
10 
(1.3)
17 
(1.0)
393 
(0.9)
0–2.1 0.9 ± 0.8
SFM 1,178 
(16.6)
63 
(3.5)
269 
(5.2)
54 
(2.9)
124 
(2.8)
122 
(6.6)
204 
(5.4)
74 
(9.2)
87 
(4.7)
100 
(3.3)
46 
(2.0)
183 
(9.1)
193 
(6.2)
68 
(11.2)
48 
(6.1)
219 
(13.1)
3,032 
(7.2)
2.0–16.6 6.7 ± 4.1
Malignant 521 
(7.4)
133 
(7.3)
889 
(17.1)
236 
(12.7)
546 
(12.5)
269 
(14.6)
329 
(8.6)
135 
(16.8)
102 
(5.6)
73 
(2.4)
79 
(3.5)
22 
(1.1)
486 
(15.7)
5 
(0.8)
63 
(8.0)
204 
(12.2)
4,092 
(9.7)
0.8–17.1 9.1 ± 5.5
Total 7,084 1,822 5,212 1,864 4,376 1,842 3,810 804 1,834 3,050 2,270 2,010 3,091 609 786 1,668 42,132
Values are presented as number (%).
TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; SD, standard deviation; UNS, unsatisfactory; ND, non-diagnostic; AUS, atypia of unde-
termined significance; FN, follicular neoplasm; SFN, suspicious for follicular neoplasm; SFM, suspicious for malignancy.
Table 3. Operation rate by each diagnostic category of TBSRTC
Diagnostic category
Range (%) Mean ± SD (%)
1 2 3 4 6 7 8 9 10 11 12 13 14 15
UNS/ND 1.6 6.5 10.2 2.5 3.2 5.3 42.2 1.9 0.5 3.9 2.9 10.2 0 14.3 0–42.2 7.5 ± 10.8
Benign 0.9 1.8 4.3 1.1 1.8 1.4 11.7 1.8 0.1 1.5 3 1.6 1.1 2.4 0.1–11.7 2.4 ± 2.8
AUS 10.5 23.2 28.1 9.5 16.4 38.7 23.9 16.5 13.3 13.8 25.9 24.5 5.5 32.6 5.5–38.7 20.2 ± 9.5
FN/SFN 45.5 60 71.1 32.1 37.5 35.7 100.0 29.1 54.5 50 42.9 0 10 0–100 43.7 ± 25.6
SFM 9.9 63.5 82.5 90.7 63.9 74 75.7 46 75 23.9 59 67.9 25 81.3 9.9–90.7 59.9 ± 24.6
Malignant 52.2 72.9 86.5 69.5 73.2 73.3 90.4 54.9 80.8 39.2 68.2 72.8 40 95.2 40–95.2 69.2 ± 17.2
Values are presented as percentage.
TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; SD, standard deviation; UNS, unsatisfactory; ND, non-diagnostic; AUS, atypia of unde-
termined significance; FN, follicular neoplasm; SFN, suspicious for follicular neoplasm; SFM, suspicious for malignancy.
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categories (DC V and VI) as positive. In this analysis, the sensi-
tivity, specificity, positive predictive value and negative predictive 
value for malignant thyroid tumors were 97.19%, 87.91%, 
98.76%, and 75.83%, respectively. Second, we included FN (DC 
IV) cases as positive and calculated each parameter for the neo-
plasm including both benign and malignant. In this case, the 
sensitivity, specificity, positive predictive value, and negative 
predictive value for neoplasm of thyroid were 97.14%, 72.89%, 
Table 5. Follow up surgical diagnosis by each DC of TBSRTC
DC
No. of 
FNA
No. of 
operation
Surgical diagnosis
PTC FTC HTC MTC PDC UC SCC MC Lym FA HA NH LT GT O
I Cyst 796 35 7 1 - - - - - - 1 3 - 22 - - 1
Acellular 3,803 212 114 4 - - 1 - - - - 17 1 64 5 1 5
Total 4,599 247 121 5 - - 1 - - - 1 20 1 86 5 1 6
II Be 19,179 375 73 11 - 1 - - - - - 34 2 240 7 - 7
LT 1,148 25 9 - - - - - - - - - - - 16 - -
GT 49 0 - - - - - - - - - - - - - - -
O 1,023 22 7 1 - - - - - - - 4 - 9 1 - -
Total 21,399 422 89 12 - 1 - - - - - 38 2 249 24 - 7
III AUS 3,708 722 471 25 4 13 1 - - - - 52 13 124 11 1 7
IV FN 283 121 20 23 3 - - - - - - 36 16 19 4 - -
V PTC 1,715 1,123 1,093 - - - - - - - - 1 - 19 10 - -
MTC 11 8 - - - 7 - - - - - - - - - 1 -
MC 2 0 - - - - - - - - - - - - - - -
Lym 1 0 - - - - - - - - - - - - - - -
O 12 2 1 - - - - - - - - - - - - 1 -
Total 1,741 1,133 1,094 - - 7 - - - - - 1 - 19 10 2 -
VI PTC 3,313 2,429 2,419 1 - - 1 - - - - - - 4 4 - -
PDC 2 2 - - - - 1 - - - - - 1 - - - -
MTC 5 3 - - - 3 - - - - - - - - - - -
UC 5 1 - - - - - 1 - - - - - - - - -
SCC 1 0 - - - - - - - - - - - - - - -
MC 8 3 - - - - - - - 1 - - - - - - 2
Lym 2 0 - - - - - - - - - - - - - - -
O 7 1 - - - - - - - - - - - - - - 1
Total 3,343 2,439 2,419 1 - 3 2 1 - 1 - - 1 4 4 - 3
DC, diagnostic category; TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carci-
noma; HTC, Hurthle cell thyroid carcinoma; MTC, medullary thyroid carcinoma; UC, undifferentiated carcinoma; SCC, squamous cell carcinoma; MC, meta-
static carcinoma; Lym, lymphoma; FA, follicular adenoma; HA, Hurthle cell adenoma; NH, nodular hyperplasia; LT, lymphocytic thyroiditis; GT, granulomatous 
thyroiditis; O, others; Be, benign; AUS, atypia of undetermined significance; FN, follicular neoplasm; PDC, poorly differentiated carcinoma.
Table 4. The malignancy rate by each diagnostic category of TBSRTC
Diagnostic category Range 
(%)
Mean ± SD
(%)1 2 3 4 6 7 8 9 10 11 12 13 14 15
UNS/ND 12/17 
(70.6)
13/25 
(52)
51/88 
(58)
4/5 
(80)
4/6 
(66.7)
10/15 
(66.7)
4/27
(14.8)
0/6 
(0)
0/2 
(0)
2/6 
(33.3)
0/6 
(0)
27/43 
(62.8)
NEa 1/1 
(100)
0–100 46.5 ± 33.5
Benign 10/32 
(31.3)
2/19
(10.5)
43/119
(36.1)
2/11
(18.2)
1/20
(5)
12/37 
(32.4)
5/48
(10.4)
3/20
(15)
0/2 
(0)
8/28
(28.6)
14/46 
(30.4)
0/20
(0)
0/5 
(0)
2/15
(13.3)
0–36.1 16.5 ± 13.1
AUS 53/94 
(56.4)
33/44 
(75)
80/101
(79.2)
28/35 
(80)
12/26 
(46.2)
123/142 
(86.6)
14/28 
(50)
19/31 
(61.3)
28/33 
(84.8)
5/12
(41.7)
18/21 
(85.7)
87/138
(63.0)
2/3 
(66.7)
12/14 
(85.7)
41.7–86.6 68.7 ± 15.8
FN/SFN 16/25 
(64)
1/3 
(33.3)
12/27 
(44.4)
5/9 
(55.6)
0/3 
(0)
0/5 
(0)
0/5 
(0)
8/16
(50)
0/6 
(0)
NEa 0/2 
(0)
3/19
(15.8)
NEa 1/1 
(100)
0–100 30.2 ± 33.1
SFM 115/117 
(98.3)
40/40 
(100)
213/222 
(95.9)
49/49 
(100)
72/78 
(92.3)
148/151 
(98)
47/56 
(83.9)
40/40 
(100)
74/75 
(98.7)
11/11 
(100)
106/108 
(98.1)
131/131 
(100)
17/17 
(100)
39/39 
(100)
83.9–100 97.5 ± 4.5
Malignant 271/272 
(99.6)
97/97 
(100)
760/769 
(98.8)
164/164 
(100)
197/197 
(100)
241/241 
(100)
120/122 
(98.4)
56/56 
(100)
59/59 
(100)
31/31 
(100)
15/15 
(100)
354/354 
(100)
2/2 
(100)
60/60 
(100)
98.4–100 99.7 ± 0.5
Values are presented as number (mal/op) (%).
TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; SD, standard deviation; UNS, unsatisfactory; ND, non-diagnostic; AUS, atypia of unde-
termined significance; FN, follicular neoplasm; SFN, suspicious for follicular neoplasm; SFM, suspicious for malignancy.
aNot evaluated due to no case of operation.
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96.78%, and 75.83%, respectively.
DISCUSSION
TBSRTC was proposed in October 2007 in Bethesda, Mary-
land, and published in 2009,1 TBSRTC was then immediately 
introduced in the 2009 guidelines of the KTA.6,16 Despite the 
information about TBSRTC having been globally disseminated, 
the status of its usage in clinical practice in Korea has been un-
known. This questionnaire provides a cross-sectional view, 
based on the collective data from participating pathology labo-
ratories, of the degree of implementation of TBSRTC in Korea 
and evaluates its impact on daily practice by assessing the inci-
dence and malignant risk of each DC at each pathology laboratory 
using TBSRTC.
Overall, the data shows that TBSRTC is well implemented 
in Korea. As of July 2012 (when the questionnaire was mailed), 
81% (60 out of 74) of the participating pathology laboratories 
were already using TBSRTC, which is higher than the rate given 
in published data from the College of American Pathologists.17 
In addition, the data demonstrates interesting technical points. 
Fifty-seven percent of the laboratories are using conventional 
alcohol-fixed direct smears as a preparatory method for thyroid 
FNA; in contrast, 14.9% of the laboratories are using liquid-
based cytology and 29.7% are using both. Overall, 44.6% of the 
laboratories are using liquid based cytology. Twenty-one out of 
74 pathology laboratories (27%) received thyroid core needle 
biopsies; among them, four institutes used both core needle biopsy 
and FNA as the primary diagnostic test for thyroid nodules. 
Although core needle biopsy of thyroid nodules is emerging as 
an effective alternative method, the primary use of core needle 
biopsy in a thyroid nodule is quite unusual. For example, current 
American Thyroid Association thyroid nodule management 
guidelines and the Society of Radiologists in Ultrasound Con-
sensus Statement have not included core biopsy as an evaluation 
tool of thyroid nodule, and some other studies suggest that after 
several non-diagnostic FNA, surgical excision should be considered 
appropriate.18,19
More importantly, our data showed some differences in the 
incidence and malignant risk of certain categories between TB-
SRTC1 or published studies from other countries7,12 and the 
current results. As shown in Table 2, lower incidence of DC IV (0.9 
± 0.8%) and higher incidence of DC III (9.7 ± 4.6%), DC V (6.7 ± 
4.1%), and DC VI (9.1 ± 5.5%) were demonstrated. Moreover, 
the malignancy rates of DC I, II, III, and V (mean of malignancy 
rates: 46.5 ± 33.5, 16.5 ± 13.1, 68.7 ± 15.8, and 97.5 ± 4.5, re-
spectively) in our study were higher than the risk of malignancy 
indicated by the original TBSRTC (1%–4%, DC I; 0%–3%, 
DC II; 5%–15%, DC III, and 60%–75%, DC V)1 and other pre-
vious studies.11,18-24 However, these findings are consistently shown 
in previous reports from Korea.8,9 These can be explained by several 
reasons. First, in Korea, the prevalence of papillary thyroid carci-
noma is more than 95%, whereas that of follicular carcinoma is 
very low, at 3.2%,6 which has resulted in the lower incidence of 
DC IV and higher incidence of DC III, V, and VI. In addition, 
higher prevalence of papillary thyroid carcinoma might influ-
ence higher malignant rates of DC II, DC III, and DC V. Second, 
most institutes submitting their details of TBSRTC are university-
based tertiary centers. In tertiary referral institutes, the patients 
who had been diagnosed with suspicious or malignant nodules 
at primary care centers were more likely to receive an operation 
despite a DC III or DC V diagnosis of FNA, especially those 
whose imaging studies strongly suggest malignancy. In the present 
study, malignancy rates were calculated based on the resected 
cases. The malignancy rate assessed either in the total fine needle 
aspiration cytology cases or in the resected cases cannot be said 
to represent the exact malignancy rate of each DC of TBSRTC. 
The former can miss unresected malignant tumors, and the latter 
can be exaggerated by selection bias, which may occur in this type 
of retrospective study. Therefore, our malignancy rates cannot be 
directly compared with the malignant risk recommended in TB-
SRTC. Lastly, because Korean citizens tend to consider false-positive 
results more significantly than false-negative results, cytopathologists 
in Korea may have a tendency to under-diagnose FNA of thyroid 
nodules.10 
There are some limitations in the data derived from this ques-
tionnaire, especially those evaluating the incidence and malig-
nancy rate of each DC in TBSRTC, as mentioned above. First, 
14 out of 16 institutes submitting the incidence and malignancy 
rate of TBSRTC are university-based centers. Therefore, the results 
of this survey may not be truly representative of all kinds of practices; 
from community to academic. Second, all data are self-reported 
and not verified. Third, the data might not reflect the current status 
in certain aspects because the questionnaire was mailed in July 
2012. The implementation of TBSRTC is more widespread in 
Korea at present, and liquid-based cytology and core needle biopsy 
are likely to have been adopted more widely. The usage of core 
needle biopsy in thyroid nodules has been actively studied in 
Korea.25 
In conclusion, overall, TBSRTC has been well adopted in 
Korea, with more than 80% of institutes using TBSRTC as of 
2012. However, ongoing education is still necessary to reduce 
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the variation of incidence and malignant rates of TBSRTC. 
Moreover, it would be better to modify reference values of ma-
lignancy rate of each category of TBSRTC and revisit the guide-
lines for treating patients with thyroid nodules in Korea based 
on the results of this study. Finally, it is highly recommended 
that each institute review their report of thyroid aspiration and 
have their own incidence and malignant rates for each DC. 
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